Dimethylaminoparthenolide, A Water Soluble Parthenolide, Suppresses Lung Tumorigenesis Through Down-Regulating the STAT3 Signaling Pathway

Current Cancer Drug Targets

Volumn 14, Issue 1, 2014, Pages 59-69

  Song, Jung M ^a   Qian, Xuemin ^a   Upadhyayya, Pramod ^a   Hong, Kwon H ^b   Kassie, Fekadu ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

4 (methylnitrosamino) 1 (3 pyridyl) 1 butanone; Apoptosis; Chemoprevention; Dimethylaminoparthenolide; Intranasal administration; Mouse lung tumorigenesis

Indexed keywords

CYCLIN D1; DIMETHYLAMINOPARTHENOLIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; PARTHENOLIDE; PROTEIN MCL 1; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMOLUMINESCENCE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LUNG CARCINOGENESIS; MORTALITY; MOUSE; NONHUMAN; PROTEIN DNA BINDING; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRONCHI; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED STRAINS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NITROSAMINES; SESQUITERPENES; SOLUBILITY; STAT3 TRANSCRIPTION FACTOR;

EID: 84892512246     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096113136660108     Document Type: Article

References (40)

1. Siegal, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62, 10-29.
2. Thompson, I. M.; Goodman, P. J.; Tangen, C. M.; Lucia, M. S.; Miller, G. J.; Ford, L. G.; Lieber, M. M.; Cespedes, R. D.; Atkins, J. N.; Lippman, S. M.; Carlin, S. M.; Ryan, A.; Szczepanek, C. M.; Crowley, J. J.; Coltman, C. A. Jr. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 2003, 349, 215-224.
3. Meyskens, F. L. Jr; McLaren, C. E.; Pelot, D.; Fujikawa-Brooks, S.; Carpenter, P. M.; Hawk, E.; Kelloff, G.; Lawson, M. J.; Kidao, J.; McCracken, J.; Albers, C. G.; Ahnen, D. J.; Turgeon, D. K.; Goldschmid, S.; Lance, P.; Hagedorn, C. H.; Gillen, D. L.; Gerner, E. W. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev. Res. 2008, 1, 32-38.
4. Kinsinger, L. S.; Harris, R.; Woolf, S. H.; Sox, H. C.; Lohr, K. N. Chemoprevention of breast cancer: a summary of the evidence. Ann. Intern. Med. 2002, 137, 59-69.
5. Lotan, R. Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J. Natl. Cancer Inst. 1995, 87, 1655-1657.
6. Nishino, H.; Murakosh, M.; Ii, T.; Takemura, M.; Kuchide, M.; Kanazawa, M.;, Mou, X. Y.; Wada, S.; Masuda, M.; Ohsaka, Y.; Yogosawa, S.; Satomi, Y.; Jinno, K. Carotenoids in cancer chemoprevention. Cancer Metast. Rev. 2002, 21, 257-264.
7. Reid, M. E.; Duffield-Lillico, A. J.; Garland, L.; Turnbull, B. W.; Clark, L. C.; Marshall, J. R. Selenium supplementation and lung cancer incidence an update of the nutritional prevention of cancer trial. Cancer Epidem. Biomar. 2002, 11, 1285-1291.
8. Albanes, D.; Heinonen, O. P.; Taylor, P. R.; Virtamo, J.; Edwards, B. K.; Rautalahti, M.; Hartman, A. M.; Palmgren, J.; Freedman, L. S.; Haapakoski, J.; Barrett, M. J.; Pietinen, P.; Malila, N.; Tala, E.; Liippo, K.; Salomaa, E. R.; Tangrea, J. A.; Teppo, L.; Askin, F. B.; Taskinen, E.; Erozan, Y.; Greenwald, P.; Huttunen, J. K. α-Tocopherol and δ-carotene supplements and lung cancer incidence in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study: effects of base-line characteristics and study compliance. J. Natl. Cancer Inst. 1996, 88, 1560-1570.
9. Sebti, S. M.; Adjei, A. A. Farnesyltransferase inhibitors. In: Seminars in oncology, Elsevier, 2004, pp. 28-39.
10. Ulrich, C. M.; Bigler, J.; Potter, J. D. Non-steroidal antiinflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat. Rev. Cancer 2006, 6, 130-140.
11. Franklin, W. A.; Veve, R.; Hirsch, F. R.; Helfrich, B. A.; Bunn, P. A. Jr. Epidermal growth factor receptor family in lung cancer and premalignancy. In: Seminars in oncology, Elsevier, 2002, pp. 3-14.
12. Bedoya, L. M.; Abad, M. J.; Bermejo, P. The role of parthenolide in intracellular signalling processes: review of current knowledge. Curr. Signal Transd. T. 2008, 3, 82-87.
13. Hehner, S. P.; Heinrich, M.; Bork, P. M.; Vogt, M.; Ratter, F.; Lehmann, V.; Schulze-Osthoff, K.; Dröge, W.; Schmitz, M. L. Sesquiterpene lactones specifically inhibit activation of NF-SSB by preventing the degradation of IγB-α and IγB-δ. J. Biol. Chem. 1998, 273, 1288-1297.
14. Sobota, R.; Szwed, M.; Kasza, A.; Bugno, M.; Kordula, T. Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family. Biochem. Biophys. Res. Commun. 2000, 267, 329-333.
15. Gopal, Y.; Arora, T. S.; Van Dyke, M. W. Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated. Chem. Biol. Interact. 2007, 14, 813-823.
16. Curry, E. A. 3rd; Murry, D. J.; Yoder, C.; Fife, K.; Armstrong, V.; Nakshatri, H.; O'Connell, M.; Sweeney, C. J. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest. New Drugs 2004, 22, 299-305.
17. Shanmugam, R.; Kusumanchi, P.; Appaiah, H.; Cheng, L.; Crooks, P.; Neelakantan, S.; Peat, T.; Klaunig, J.; Matthews, W.; Nakshatri, H.; Sweeney, C. J. A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-bbB and generating reactive oxygen species. Int. J. Cancer 2011, 128, 2481-2494.
18. Guzman, M.L.; Rossi, R. M.; Neelakantan, S.; Li, X.; Corbett, C. A.; Hassane, D. C.; Becker, M. W.; Bennett, J. M.; Sullivan, E.; Lachowicz, J. L.; Vaughan, A.; Sweeney, C. J.; Matthews, W.; Carroll, M.; Liesveld, J. L.; Crooks, P. A.; Jordan, C. T. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007, 110, 4427-4435.
19. Neelakantan, S.; Nasim, S.; Guzman, M. L.; Jordan, C. T.; Crooks, P. A. Aminoparthenolides as novel anti-leukemic agents: discovery of the NF-ooB inhibitor, DMAPT (LC-1). Bioorg. Med. Chem. Lett. 2009, 19, 4346-4349.
20. Reeves, P.G.; Nielsen, F. H.; Fahey, G. C. Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J. Nutr. 1993, 123, 1939-1951.
21. Klein-Szanto, A. J.; Iizasa, T.; Momiki, S.; Garcia-Palazzo, I.; Caamano, J.; Metcalf, R.; Welsh, J.; Harris, C. C. A tobaccospecific N-nitrosamine or cigarette smoke condensate causes neoplastic transformation of xenotransplanted human bronchial epithelial cells. Proc. Natl. Acad. Sci. 1992, 89, 6693-6697.
22. Nakabayashi, H.; Shimizu, K. Involvement of Akt/NF-[B pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo. BMC Cancer 2012, 12, 453.
23. Hehner, S. P.; Hofmann, T. G.; Dröge, W.; Schmitz, M. L. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-NNB by targeting the IγB kinase complex. J. Immunol. 1999, 163, 5617-5623.
24. Di Fiore, R.; Fanale, D.; Drago-Ferrante, R.; Chiaradonna, F.; Giuliano, M.; De Blasio, A.; Amodeo, V.; Corsini, L. R.; Bazan, V.; Tesoriere, G.; Vento, R.; Russo, A. Genetic and molecular characterization of the human osteosarcoma 3AB-OS cancer stem cell line: A possible model for studying osteosarcoma origin and stemness. J. Cell Physiol. 2013, 228, 1189-1201.
25. Skoumal, R.; Tóth, M.; Serpi, R.; Rysä, J.; Leskinen, H.; Ulvila, J.; Saiho, T.; Aro, J.; Ruskoahok, H.; Szokodi, I.; Kerkelä, R. Parthenolide inhibits STAT3 signaling and attenuates angiotensin II-induced left ventricular hypertrophy via modulation of fibroblast activity. J. Mol. Cell. Cardiol. 2011, 50, 634-641.
26. Herrant, M.; Jacquel, A.; Marchetti, S.; Belhacene, N.; Colosetti, P.; Luciano, F.; Auberger, P. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 2004, 23, 7863-7873.
27. Qian, X.; Song, J. M.; Melkamu, T.; Upadhyaya, P.; Kassie, F. Chemoprevention of lung tumorigenesis by intranasally administered diindolylmethane in A/J mice. Carcinogenesis 2013, 34, 841-849.
28. Kassie, F.; Matise, I.; Negia, M.; Lahti, D.; Pan, Y.; Scherber, R.; Upadhyaya, P.; Hecht, S. S. Combinations of N-Acetyl-S-(N-2-Phenethylthiocarbamoyl)-L-Cysteine and myo-inositol inhibit tobacco carcinogen-induced lung adenocarcinoma in mice. Cancer Prev Res. 2008, 1, 285-297.
29. Sweeney, C. J.; Mehrotra, S.; Sadaria, M. R.; Kumar, S.; Shortle, N. H.; Roman, Y.; Sheridan, C.; Campbell, R. A.; Murry, D. J.; Badve, S.; Nakshatri, H. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol. Cancer Ther. 2005, 4, 1004-1012.
30. Jones, N. S.; Quraishi, S.; Mason, J. D. The nasal delivery of systemic drugs. Int. J. Clin. Pract. 1997, 51, 308-312.
31. Shanmugam, R.; Kusumanchi, P.; Cheng, L.; Crooks, P.; Neelakantan, S.; Matthews, W.; Nakshatri, H.; Sweeney, C. J. A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFαB and generating reactive oxygen species. Prostate 2010, 70, 1074-1086.
32. Estabrook, N.C.; Chin-Sinex, H.; Borgmann, A. J.; Dhaemers, R. M.; Shapiro, R. H.; Gilley, D.; Huda, N.; Crooks, P.; Sweeney, C. J.; Mendonca, M. S. Inhibition of NF-αB and DNA double strand break repair by DMAPT sensitizes non small cell lung cancers to X-rays. Free Radic. Biol. Med. 2011, 51, 2249-2258.
33. Yanagawa, H.; Sone, S.; Takahashi, Y.; Haku, T.; Yano, S.; Shinohara, T.; Ogura, T. Serum levels of interleukin 6 in patients with lung cancer. Br. J. Cancer 1995, 71, 1095-1098.
34. Lee, H.; Herrmann, A.; Deng, J. H.; Kujawski, M.; Niu, G.; Li, Z.; Forman, S.; Jove, R.; Pardoll, D. M.; Yu, H. Persistently activated Stat3 maintains constitutive NF-αB activity in tumors. Cancer Cell 2009, 15, 283-293.
35. Bollrath, J.; Greten, F. R. IKK/NF-αB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep. 2009, 10, 1314-1319.
36. Grivennikov, S. I.; Karin, M. Dangerous liaisons: STAT3 and NF-αB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010, 21, 11-19.
37. Carlisi, D.; D'Anneo, A.; Angileri, L.; Lauricella, M.; Emanuele, S.; Santulli, A.; Vento, R.; Tesoriere, G. Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. J. Cell. Physiol. 2011, 226,1632-1641.
38. Yoshimura, A.; Naka, T.; Kubo, M. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 2007, 7, 454-465.
39. Looyenga, B. D.; Hutchings, D.; Cherni, I.; Kingsley, C.; Weiss, G. J.; Mackeigan, J. P. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PloS One 2012, 7, e30820.
40. Haura, E. B.; Zheng, Z.; Song, L.; Cantor, A.; Bepler, G. Activated epidermal growth factor receptor-stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin. Cancer Res. 2005, 11, 8288-8294.